Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.

Gynecol Oncol 2015 Oct 29;139(1):118-26. Epub 2015 Jul 29.

KU Leuven - University of Leuven, University Hospitals Leuven, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, B-3000 Leuven, Belgium; Gynaecological Oncology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek, Amsterdam, The Netherlands. Electronic address:

Objective: Endometrial carcinoma (EC) is the sixth most common cancer in women and therapies are limited for advanced and recurrent disease. Patient-derived tumor xenograft (PDTX) models are becoming popular tools in translational research because of their histological and genetic similarity to the original tumors and the ability to predict therapeutic response to treatments. Here, we established and characterized a panel of 24 EC PDTX models which includes the major histological and genetic subtypes observed in patients.

Methods: Fresh tumor tissues collected from primary, metastatic and recurrent type I and type II EC patients were engrafted in immunocompromised mice. Histology, vimentin, and cytokeratin expression were evaluated, together with Microsatellite instability (MSI), mutation profiling by Whole Exome Sequencing and copy number profiling by Whole Genome Low Coverage Sequencing. The efficacy of both PI3K and MEK inhibitors was evaluated in a model of endometrioid carcinoma harboring PTEN, PIK3CA and KRAS mutations.

Results: We observed good similarity between primary tumors and the corresponding xenografts, at histological and genetic level. Among the engrafted endometrioid models, we found a significant enrichment of MSI and POLE mutated tumors, compared to non-engrafted samples. Combination treatment with NVP-BEZ235 and AZD6244 showed the possibility to stabilize the tumor growth in one model originated from a patient who already received several lines of chemotherapy.

Conclusion: The established EC PDTX models, resembling the original human tumors, promise to be useful for preclinical evaluation of novel combination and targeted therapies in specific EC subgroups.

Download full-text PDF

Source
http://ac.els-cdn.com/S0090825815300895/1-s2.0-S009082581530
Web Search
http://dx.doi.org/10.1016/j.ygyno.2015.07.104DOI Listing
October 2015
21 Reads

Publication Analysis

Top Keywords

histological genetic
12
pdtx models
12
tumor xenograft
8
targeted therapies
8
preclinical evaluation
8
patient-derived tumor
8
models
5
tumor growth
4
patients engrafted
4
mice histology
4
growth model
4
immunocompromised mice
4
model originated
4
engrafted immunocompromised
4
vimentin cytokeratin
4
possibility stabilize
4
evaluated microsatellite
4
pole mutated
4
expression evaluated
4
cytokeratin expression
4

Similar Publications